ࡱ; nk  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijmoRoot Entry  \pCalc Ba=> =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_) #,##0.00                + ) , *  (8 (8 (  $   (    $  $  $    ( ( `"VMcondensed balance sheets u":Wcondensed statements of op"`condensed statements of ca!mnet income loss per share"Vq3 shortterm investment sec v4 property and equipment{5 intangible assets 5 intangible assets-16 accrued expenses"8 share based compensation#restricted stock units rsusА stock optionsstock options-1"Vcorporate office manufact"2research and development i"ܢgeneral and administrative zm$$general and administrative-1²item 6 exhibits"section 302 of the sarbane$>section 302 of the sarbane-1$section 302 of the sarbane-2$section 302 of the sarbane-3$$section 302 of the sarbane-4$section 302 of the sarbane-5$\section 302 of the sarbane-6$~section 302 of the sarbane-7"certificationpursuant to s$&certificationpursuant to s-1$Pcertificationpursuant to s-2$certificationpursuant to s-3TJB|      3  @@   c' CONDENSED BALANCE SHEETS (Unaudited)July 31, 2018October 31, 2017ASSETSCurrent Assets:Cash and cash equivalentsRestricted cash$Short-term investment securities-Income tax receivableDeferred expenses-Prepaid expenses and other current assetsTotal current assets<Property and equipment (net of accumulated depreciation)7Intangible assets (net of accumulated amortization)Other assetsTotal assets(LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payableAccrued expensesDeferred revenueOther current liabilitiesTotal current liabilitiesOther liabilitiesTotal liabilities*Commitments and contingencies  Note 9Stockholders equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at July 31, 2018 and October 31, 2017 Liquidation preference of $0 at July 31, 2018 and October 31, 2017Common stock - $0.001 par value; 95,000,000 shares authorized, 52,802,360 and 41,206,538 shares issued and outstanding at July 31, 2018 and October 31, 2017Additional paid-in capitalAccumulated deficitTotal stockholders equity.Total liabilities and stockholders equity# CONDENSED STATEMENTS OF OPERATIONS!Three Months Ended July 31, Nine Months Ended July 31,20182017RevenueOperating expenses:%Research and development expenses'General and administrative expensesTotal operating expensesLoss from operationsOther income (expense):Interest income, net7Net changes in fair value of derivative liabilitiesOther expense,Net loss before benefit for income taxesIncome tax expense Net loss0Net loss per common share, basic and dilutedKWeighted average number of common shares outstanding, basic and diluted% CONDENSED STATEMENTS OF CASH FLOWSNine Months Ended July 31,OPERATING ACTIVITIESOAdjustments to reconcile net loss to net cash used in operating activities:Stock compensation(Employee stock purchase plan expense?Gain on change in value of warrants and embedded derivative.Loss on disposal of property and equipment"Write-off of intangible assetsDepreciation expense-Amortization expense of intangible assets:Net (accretion) amortization of premiums and discounts/Change in operating assets and liabilities:)Accounts payable and accrued expenses)Net cash used in operating activitiesINVESTING ACTIVITIES@Restricted cash established with letter of credit agreements1Purchases of short-term investment securities@Proceeds from maturities of short-term investment securities&Purchase of property and equipmentCost of intangible assets7Net cash provided by (used in) investing activitiesFINANCING ACTIVITIES,Net proceeds of issuance of common stock&Proceeds from exercise of warrants.Proceeds from employee stock purchase planJTax withholdings paid related to net share settlement of equity awards3Employee tax withholdings paid on equity awardsITax shares sold to pay for employee tax withholdings on equity awards-Net cash provided by financing activities8Net increase (decrease) in cash and cash equivalents4Cash and cash equivalents at beginning of period.Cash and cash equivalents at end of period&SUPPLEMENTAL CASH FLOW INFORMATIONCash paid for taxes@SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIESCAccounts payable and accrued expenses settled with common stock$-LProperty and equipment included in accounts payable and accrued expenses Net Income (Loss) per ShareAs of July 31,WarrantsStock OptionsRestricted Stock UnitsTotal$ 3. SHORT-TERM INVESTMENT SECURITIES Amortized cost, as adjusted#Gross unrealized holding gains$Gross unrealized holding lossesEstimated fair valueShort-term investments:Certificates of Deposit&Domestic Governmental Agency LoansU.S Treasury Notes*Total short-term investment securities 4. PROPERTY AND EQUIPMENTLeasehold improvementsLaboratory equipmentFurniture and fixturesComputer equipmentConstruction in progress Total property and equipment-Accumulated depreciation and amortizationNet property and equipment 5. INTANGIBLE ASSETSPatentsLicensesSoftwareTotal intangiblesAccumulated amortizationIntangible assetsYear ended October 31,2018 (Remaining)2019202020212022 Thereafter 6. ACCRUED EXPENSES:#Salaries and other compensationVendorsProfessional feesTotal accrued expenses 8. SHARE BASED COMPENSATIONThree Months Ended July 31,Nine Months Ended July 31,Research and developmentGeneral and administrative Restricted Stock Units (RSUs)Number of RSUs'Weighted-AverageGrant Date Fair ValueBalance at October 31, 2017GrantedVested CancelledBalance at July 31, 2018 Stock OptionsNumber of Options%Weighted-Average Exercise Price$Outstanding at October 31, 2017:Canceled or Expired Outstanding at July 31, 2018+Vested and Exercisable at July 31, 2018Expected Term:5.35  6.51 years85.50-6.50 yearsExpected Volatility94.61% - 100.34%107.07%-110.93%Expected Dividends0%Risk Free Interest Rate 1.81  2.93% 1.26%-1.58%0 Corporate Office & Manufacturing Facility Lease2018 (remaining)* Research and Development (in thousands) %Three Months Ended July 31,Increase (Decrease)$%HPV-associated cancers(29)%6Neoantigen-based therapies (ADXS-NEO and ADXS-HOT)Other expensesPartner reimbursements(Total research & development expense(39QStock-based compensation expense included in research and development expense(64$ General and Administrative Expenses&General and administrative expense(75SStock-based compensation expense included in general and administrative expense(89 m(5(19(45(56(82 Item 6. Exhibits31.1*gCertification of Principal Executive, Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200231.2*fCertification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200232.1*fCertification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 200232.2*. SECTION 302 OF THE SARBANES OXLEY ACT OF 2002bI have reviewed this report on Form 10-Q for the quarter ended July 31, 2018 of Advaxis, Inc.;6Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;#Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;PThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and<  procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)zDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)sDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; andAll significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.By:/s/ Kenneth A. BerlinName:Kenneth A. BerlinTitle:)President and Chief Executive Officer. SECTION 302 OF THE SARBANES OXLEY ACT OF 2002^I have reviewed this report on Form 10-Q for the quarter ended July 31, 2018 of Advaxis, Inc.;*Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;DThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:nDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;gDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andwDisclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting./s/ Molly HendersonMolly Henderson1Executive Vice President, Chief Financial OfficerH CERTIFICATION-PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002vFully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; andkFairly presents, in all material respec<ts, the financial condition and result of operations of the Company.September 10, 2018/s/ Kenneth A. BerlinKenneth A. Berlin%President and Chief Executive Officer > cc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } (,@,@,,,,, , , , ,,,,,,,,,,,,,,,,      ~ *h~ ru ~ F~ .  ~   ~ E  ~ N~ .  ~ N$~ -  ~ ~ n  ~ fu~ o ~ vR~ K ~ ~  ~ ~ *   ~ j,~ P ~ :=~  ~ E~ Nm ~  ~  ~ :~ F ~ V~  ~ ~ > ~ B~ Zg !,",#,$,%,&,', ! " " " #~ #~ # $~ $V~ $ %~ %~ % & ~ &~ &O '!~ ''~ '*'Z ''''PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } }  }  } } }  } ,@ @,@,,, , , , ,,,,,,,,,, " #  $  % &  %  &      '~ ~ /~  M ~ r ( )~ ¨~  ~ \~  *~ >F~ .~ ~~ 6 +~ ~ 6/~ :?~ N ,~ "~ ~~  ~ & - .~ V~ ~  ~   /    ~ R 0~ ~ ~  Z~  1~ $~ >~  ~ R 2  ~  ~  3~ $~ >~  N ~  4~ ~ ~   ~ K 5~ ާ ~  ~  Bo ~ r       PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} O} }  } }  } 5,@ @,@,,,, , , , , ,,,,,,,,,,,,,,,,,, 6 7 % &   8 3~ N~  9 :~ ]~ ځ ;~ 6~ J < ~  =~ n~  >~ ~  ?~  ~  @~ ~  A~ ~ Z B  ~ ~ v  ~ E~ ' ~ ~ > C~ *~ : ~ ޶~ zc ~ b~ 2 D~ ~ :k E F~   G~ <~  H~ .~ 2U I~ n~  J~ R~  ,",#,$,%,&,',(,),+,,,-,/,0,2,3,@4, K~ ~ ~ "L #M~ #H~ # $N $~ $ %O~ %Z~ %6 &P~ &~ &z 'Q~ '~ ' (R~ (~ ( )S~ )vG~ )& +T~ +~ + ,U~ ,ru~ , -V~ -*h-~ -- /W 0X~ 00~ 00 2Y 3Z 3[3~ 3.3 4\ 4~ 4Zr----00003333PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@,@,@,,,, ] ^ % & _~ ~ vڼ `~ jC~ ڤ a~ .+~ 6>] b~ H+~ "PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} *} }  } } }  } } }  }  ,@,@ @,,@,, ,@ c   d e  f  g h i~  [  [ ~  j~    ~  k~ . ~  f~  l~   [ ~ f ~  r     PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} -} }  } }  }  ,@,@,,,,, , , , , m     n~ >#~ ! o~ V~ vD p~  ~ f q~ f~ . r~  ~  s~ .~  t~ :~ & u~ fu ~ o J   PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@,@,,,,, , , v     w~ >c~ ~Y x~ & ~ & y~ ~  z~ 6q~ Vg {~ B~  |~ vR ~ K J   PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  ,,,,,,,, , }   ~~  ~ * ~  ~  ~  ~ 9 b~ vR " PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} #} }  } }  }  ,@,@,,,,,      ~ n~ v) ~ v ~ + ~ Z~ 2 ~ :=~ J PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  } } }  } ,@,@,@,,,      % &  %  & ~ ~~ ~  $ ~ B ~ ~ ~  8~ ? b~ ~ ~  ] ~ ځz    PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,@ @,,,,, ,      ~ 2SGz!@ ~ "8~  ~ c~ ; ~ P~  ~ .+~   : PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} +} }  } }  }  ,@ @,,,,,    ~ ڤ~  ~ ~ C ~ .ξ~  ~ jC~  ~ 7~ *PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } :} } 8} ,@,@,,,,,  % &              *PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  ,@,,,,,, , , ,  }   ~  ~ N ~ F ~  ~ f ~ jD b~  * PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Q} }  } }  }  } } }  } }  ,@ @ ,@,,,, , , ,      % &        ~ B~ ]~  N    ~  ~ ~  N~ > ~  r~ v ~  d~  ~ ~ B~ G~  ~ ¨ ~   ~     ~ ~ ~  ~            PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} S} } } }  ,@ @ ,@,,,  #    % &        ~ >F~ .~  -    ~ ~ ~  2M        PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Q} }  } }  }  } } }  } }  ,@ @ ,@,,,, , , ,  $    % &        ~ B~ ~  z    ~ f~ ~  r~ * ~ ~ s~  5~  ~ v~ bs~ F~ : ~ \ ~  ~ r    ~ $ ~ B ~            PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} S} } } }  ,@ @ ,@,,,  #    % &        ~ ~~ 6~  J    ~ 8~ ?~          PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d}  ,@,,, ,          PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } d}  ,@,,, , ~  ~  ~  ~   PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,,        PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,    PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } )} ,,,  !    PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } d}  ,@,,, , ~  ~  ~  ~   PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,,,        PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,    PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } 1} ,,,  !    PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } d} ,@,, ~  ~   PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} %} ,,,,  !  PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } d} ,@,, ~  ~   PHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 1} ,,,,  !  PH|0(  |>@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@c@c՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFlWorkbookCompObjIOle SummaryInformation(DocumentSummaryInformation8h